CO-OWNERSHIP AGREEMENTCo-Ownership Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
Considering the beneficiary contract no. ANR-10-SATT-04-01 signed between the Agence Nationale de la Recherche, Université Pierre et Marie Curie, Université de technologie de Compïègne, Université Panthéon Assas, institut Européen d’Administration des Affaires and Centre National de la Recherche Scientifique [National Centre for Scientific Research], in the presence of the Caisse des Dépôts et Consignation [Bank for Official Deposits] on 17 January 2012;
Services Agreement relating to the SARA-INT clinical data platform Between Biophytis SA as Client and BlueCompanion as Service ProviderServices Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
The Client and the Service Provider are hereinafter collectively referred to as the Parties and individually as a Party.
LICENSE AGREEMENTLicense Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
· The Company BIOPHYTIS, limited company with a capital of 1,221,767 euros, whose registered office is situated at 14 Avenue de l’Opéra - 75001 Paris, registered in the Trade and Companies Register of Paris under number B 492 002 225, represented by Stanislas VEILLET, its Chief Executive Officer, duly authorised for the purposes hereof,
CO-OWNERSHIP AGREEMENT A PARTIAL ASSIGNMENT OF SHARECo-Ownership Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
The UPMC, INSERM and INSERM TRANSFERT, the CNRS and the COMPANY are hereinafter jointly or individually referred to as “PARTY” or “PARTIES”. It is specified that any notification of the PARTIES or to the PARTIES is validly made, with regard to INSERM, by or to INSERM TRANSFERT.
ASSIGNMENT AGREEMENTAssignment Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
BIOPHYTIS, a Société anonyme with a share capital of 2 692 682 euros, organized under the laws of France, with its registered office located at 14 Avenue de l’Opéra — 75001 Paris, registered with the Paris Trade and Companies Registry number 492 002 225, represented by Nadine Coulm and Dimitri Batsis, duly authorized for the purposes hereof,
AMENDMENT No. 1 TO THE LICENSE AGREEMENTLicense Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
· The company BIOPHYTIS, a public limited company with share capital of 2,692,682 euros, with registered office at 14 Avenue de l’Opéra - 75001 Paris, registered in the Trade and Companies Register of Paris, under number B 492 002 225, represented by Stanislas VEILLET, its Managing Director, duly authorised for this purpose,
CO-OWNERSHIP AGREEMENT CONSIDERED AS TRANSFER OF SHARECo-Ownership Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
1°) THE INSTITUT BIOPHYTIS, simplified joint stock company with a capital of €753,927, SIRET no. 492002225000018, having its head office at 14 avenue de l’Opéra 75001 Paris, represented by its Chairman, Mr Stanislas VEILLET, hereinafter referred to as the ‘COMPANY”,
Amendment to the Services Agreement relating to the SARA-DATA Clinical Data Platform Between Biophytis SA as Client and BlueCompanion as Service ProviderServices Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
GOODWILL PLEDGE AGREEMENT In agreement with the parties, this agreement has been bound by the ASSEMBLACT R.C. process, preventing any substitution or addition and is only signed on the last pageGoodwill Pledge Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
1, Biophytis S.A., a public limited company with capital of 2,692,682.60 EUR, whose registered office is located at 14, avenue de l’Opéra - 75001 Paris, identified under the unique number 492 002 225 of the RCS [Trade and Companies Register] of Paris, whose securities are listed on the organised multilateral trading facility Euronext Growth under ISIN number FR0012816825, represented by Mr Stanislas Veillet as Chairman and Chief Executive Officer;
Amendment to the Services Agreement relating to the SARA-INT Clinical Data Platform Between Blophytis SA as Client and BlueCompanion as Service ProviderServices Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
CO-OWNERSHIP AGREEMENT L08142Co-Ownership Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
1°) BIOPHYTIS INSTITUTE, simplified joint-stock company with a capital of €63,000, SIRET no. 492002225000018, whose registered office is located at 14 avenue de l’Opéra 75001 Paris, represented by its Chairman, Mr Stanislas VEILLET, hereinafter referred to as the “COMPANY”,
Services agreement Between Biophytis, Inc. And Biophytis SA Reed Smith LLPServices Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
The Service Provider and the Client are hereinafter collectively referred to as the “Parties” or individually as a “Party”.
BONDS ISSUE AGREEMENT By and betweenBonds Issue Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
This agreement (hereinafter referred to as the “Agreement” or “Bonds Issue Agreement”) is entered into on September 10th, 2018, by and between:
Amendment n°1 to the Services Agreement Between Biophytis, Inc. And Biophytis SA Reed Smith LLP 112, avenue Kléber 75782 Paris Cedex 16 - France Téléphone : +33 (0)1 76 70 40 00 Fax: +33 (0)1 76 70 41 19Services Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
VENTURE LOAN AGREEMENT By and between Biophytis S.A. as Issuer and Kreos Capital V (UK) Ltd. As SubscriberVenture Loan Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
This venture loan agreement (hereinafter referred to as the “Venture Loan Agreement”) is entered into on September 10th, 2018, by and between:
Amendment to the Services AgreementServices Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
PORTIONS OF THIS EXHIBIT IDENTIFIED BY [*****] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. UPMC Ref.: C16/1007A01 AMENDMENT 1 TO THE...Collaboration Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
University Pierre et Marie Curie (Paris 6), a scientific, cultural and professional public institution with registered office at 4, Place Jussieu 75252 Paris Cedex 5
COLLABORATION AGREEMENTCollaboration Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
· SORBONNE UNIVERSITY, a scientific, cultural and professional public institution, Siret [French businesses directory] 130 023 385 00011, APE [primary business activity] code 8542Z, having its registered office at 21 rue de l’École de Médecine, 75006 Paris, represented by its President, Mr Jean CHAMBAZ,
COLLABORATION AGREEMENTCollaboration Agreement • November 20th, 2020 • Biophytis SA • Pharmaceutical preparations
University Pierre et Marie Curie (Paris 6), a scientific, cultural and professional public institution with registered office at 4, Place Jussieu 75252 Paris Cedex 5 Represented by Professor Jean CHAMBAZ, President,
